University of Illinois

Spectrum Pharmaceuticals, Inc.

Midwestern University

Pharmazz, Inc.

Anil Gulati

Guru Reddy

Luigi Lenaz

Kartike Gulati

Manish Lavhale

Shridhar V Andurkar

Abhishek Kumar Singh

Bhawna Katia

Reddy Guru

Manish S Lavhale

Methods of treating hypertension, pain, and resuscitative hemorrhagic shock using an adrenergic agent, like centhaquin, are disclosed. The methods treat mammals, including humans.

Therapeutic treatments using centhaquin

The present invention relates to compositions and methods for treating neuropsychiatric disorders in vertebrates and humans. More specifically, the present invention provides for use of IRL-1620, an endothelin-B receptor agonist, in appropriate doses to be a neuroprotective and a neuroregenerative agent. Accordingly, in one aspect the disclosure provides a method of treating a neuropsychiatric disorder comprising administering to a patient in need thereof a therapeutically effective amount of an endothelin-B receptor agonist to treat the neuropsychiatric disorder. In some embodiments, the endothelin-B receptor agonist is co-administered with an additional agent to treat the neuropsychiatric disorder. In some embodiments, the additional agent is selected from the group consisting of an antidepressant, an anti-inflammatory agent, a CNS stimulant, a neuroleptic, and an anti-proliferative agent.

Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist

Methods of using an ETreceptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETreceptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.

[object Object]

Methods of treating diabetic ketoacidosis are disclosed. The methods utilize an endothelin antagonist to treat diabetic ketoacidosis in mammals, including humans.

Method and composition for treating diabetic ketoacidosis

Methods of imaging tumors are disclosed. The methods utilize an endothelin ETreceptor agonist or an endothelin ETreceptor antagonist, in combination with an imaging agent, to detect a tumor in mammals, including humans.

Methods to sensitize tumor cells to radiation therapy through the administration of an endothelin agonist such as the ETagonist IRL1620.

Sensitization of tumor cells to radiation therapy through administration of endothelin agonists

Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ET) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.

Methods, compositions and articles of manufacture for contributing to the treatment of cancers

Methods, compositions and articles of manufacture for contributing to the treatment of a solid cancerous tumor are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ET) to enhance the delivery of a chemotherapeutic agent to a solid tumor in mammals, including humans.

Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors

Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ET) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).

Methods and compositions for contributing to the treatment of cancers

Methods for treatment of stroke or cerebrovascular accidents using an ETB receptor agonist

Composition and methods of treating pain and reducing or reversing tolerance to opiate analgesics are disclosed. The composition and method utilize an opiate analgesic and an endothelin antagonist as active agents to treat pain in mammals, including humans.

Growing community of inventors

Naperville, IL, United States of America

Anil Gulati